
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops
Design Therapeutics has reported positive outcomes from the double-masked, randomised Phase I trial of its GeneTAC small molecule, DT-168, in healthy volunteers. The single and multiple-ascending dose (SAD/MAD) trial assessed the tolerability, safety, …